Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 in sorafenib-refractory hepatocellular carcinoma
NCT01375569Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2011
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Jun 2011; status: completed.
02
Drugs
carotuximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01375569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01375569.